Genmab A/S (GMAB) vs BeOne Medicines (ONC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Genmab A/S (GMAB) has outperformed BeOne Medicines (ONC) over the past year, gaining 10.1% versus a loss of 0.3%. Over five years, ONC leads with a -2.3% price change compared with -18.9% for GMAB. BeOne Medicines is the larger company by market cap ($39.83 billion vs $22.17 billion), about 1.8 times the size.
On valuation, Genmab A/S trades at a lower forward P/E (23.6x vs 34.2x for BeOne Medicines). Genmab A/S converts more of its revenue into profit, with a net margin of 25.9% versus 5.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | ONC |
|---|---|---|
| Share price | $36.05 | $350.13 |
| Market cap | $22.17B | $39.83B |
| 1-day change | -1.64% | -3.82% |
| YTD return | +17.05% | +15.25% |
| 1-year return | +10.11% | -0.27% |
| 5-year return | -18.86% | -2.32% |
| P/E ratio (TTM) | 28.39 | 62.64 |
| Forward P/E | 23.64 | 34.15 |
| EPS (TTM) | $1.27 | $5.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.72B | $5.34B |
| Revenue growth (YoY) | +19.19% | +40.23% |
| Net income (latest FY) | $963.00M | $286.93M |
| Gross margin | 93.60% | 87.49% |
| Operating margin | 28.63% | 8.37% |
| Net margin | 25.89% | 5.37% |
| 52-week high | $40.17 | $385.22 |
| 52-week low | $23.62 | $253.95 |
| Distance from 52-week high | -10.26% | -9.11% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +19.89% | +24.30% |
| Average volume | 2.83M | 388.88K |
| Shares outstanding | 614.90M | 104.92M |
| Employees | 3,119 | 12,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GMAB has outperformed ONC by 10.4 percentage points over the past year.
- BeOne Medicines trades at a higher earnings multiple (62.6x vs 28.4x trailing P/E).
- Genmab A/S is more profitable, keeping 25.9 cents of every revenue dollar as net income versus 5.4 cents for BeOne Medicines.
- BeOne Medicines grew revenue faster in its latest fiscal year (+40.23% vs +19.19%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
GMAB vs ONC FAQ
Which is bigger, Genmab A/S or BeOne Medicines?
BeOne Medicines (ONC) is larger, with a market capitalization of $39.83B compared with $22.17B for Genmab A/S (GMAB).
Which stock has performed better over the past year, GMAB or ONC?
GMAB returned +10.11% over the past 12 months, compared with -0.27% for ONC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMAB or ONC?
GMAB has the lower trailing P/E at 28.4, versus 62.6 for ONC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Genmab A/S and BeOne Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.